Mostrar el registro sencillo del ítem
dc.contributor.author | Sereno, María | |
dc.contributor.author | Gutiérrez-Gutiérrez, Gerardo | |
dc.contributor.author | Rubio, Juan Moreno | |
dc.contributor.author | Apellániz-Ruiz, María | |
dc.contributor.author | Sánchez-Barroso, Lara | |
dc.contributor.author | Casado, Enrique | |
dc.contributor.author | Falagan, Sandra | |
dc.contributor.author | López-Gómez, Miriam | |
dc.contributor.author | Merino, María | |
dc.contributor.author | Gómez-Raposo, César | |
dc.contributor.author | Rodriguez-Salas, Nuria | |
dc.contributor.author | Tébar, Francisco Zambrana | |
dc.contributor.author | Rodriguez Antona, Cristina | |
dc.date.accessioned | 2019-04-04T08:50:41Z | |
dc.date.available | 2019-04-04T08:50:41Z | |
dc.date.issued | 2017-01-19 | |
dc.identifier.citation | BMC Cancer. 2017;17(1):63. | es_ES |
dc.identifier.issn | 1471-2407 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/7434 | |
dc.description.abstract | BACKGROUND: Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around 60-80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology of oxaliplatin neurotoxicity remains unclear. SCN9A is a gene codifying for a subtype sodium channel (type IX, subunit α) and mutations in this gene are involved in neuropathic perception. In this study we investigated whether SCN9A genetic variants were associated with risk of neurotoxicity in patients diagnosed of cancer on treatment with oxaliplatin. METHODS: Blood samples from 94 patients diagnosed of digestive cancer that had received oxaliplatin in adjuvant or metastatic setting were obtained from three hospitals in Madrid. These patients were classified into two groups: "cases" developed oxaliplatin-induced grade 3-4 neuropathy (n = 48), and "controls" (n = 46) had no neuropathy or grade 1. The neuropathy was evaluated by an expert neurologist and included a clinical examination and classification according to validated neurological scales: National Cancer Institute Common Toxicity Criteria (NCI-CTC), Oxaliplatin-Specific Neurotoxicity Scale (OSNS) and Total Neuropathy score (TNS). Genotyping was performed for 3 SCN9A missense polymorphisms: rs6746030 (R1150W), rs74401238 (R1110Q) and rs41268673 (P610T), and associations between genotypes and neuropathy were evaluated. RESULTS: We found that SCN9A rs6746030 was associated with protection for severe neuropathy (OR = 0.39, 95% CI = 0.16-0.96; p = 0.041). Multivariate analysis adjusting for diabetes provided similar results (p = 0.036). No significant differences in neuropathy risk were detected for rs74401238 and rs41268673. CONCLUSION: SCN9A rs6746030 was associated with protection for severe oxaliplatin-induced peripheral neuropathy. The validation of this exploratory study is ongoing in an independent series. | es_ES |
dc.description.sponsorship | For all the patients who accepted to participate in this investigation. Funding This work was supported by projects from the“Spanish Ministry of Economy and Competiveness”(grant number SAF2015-64850-R) and from Carlos III Health Institute project: PI12/02824 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central (BMC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Calcium channel | es_ES |
dc.subject | Oxaliplatin neuropathy | es_ES |
dc.subject | SCN9A | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Aged | es_ES |
dc.subject.mesh | Aged, 80 and over | es_ES |
dc.subject.mesh | Antineoplastic Agents | es_ES |
dc.subject.mesh | Biomarkers, Tumor | es_ES |
dc.subject.mesh | Digestive System Neoplasms | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Follow-Up Studies | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Lymphatic Metastasis | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | NAV1.7 Voltage-Gated Sodium Channel | es_ES |
dc.subject.mesh | Neoplasm Staging | es_ES |
dc.subject.mesh | Organoplatinum Compounds | es_ES |
dc.subject.mesh | Oxaliplatin | es_ES |
dc.subject.mesh | Peripheral Nervous System Diseases | es_ES |
dc.subject.mesh | Polymorphism, Genetic | es_ES |
dc.subject.mesh | Prognosis | es_ES |
dc.subject.mesh | Survival Rate | es_ES |
dc.title | Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 28103821 | es_ES |
dc.format.volume | 17 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 63 | es_ES |
dc.identifier.doi | 10.1186/s12885-016-3031-5 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1471-2407 | es_ES |
dc.identifier.journal | BMC cancer | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Epidemiología Genética y Molecular | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2015-64850-R | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI12/02824 | es_ES |
dc.rights.accessRights | open access | es_ES |